Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Sponsor: Adelphi Real World
Summary
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Official title: Clinical Characteristics, Treatment Patterns and Outcomes in Patients With axSpA and PsA Following Initiation of Bimekizumab, Risankizumab, Guselkumab, Upadacitinib or a TNF Inhibitor
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
700
Start Date
2025-07-07
Completion Date
2027-03
Last Updated
2025-09-10
Healthy Volunteers
No
Interventions
observational study
This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
Locations (1)
Royal National Hospital for Rheumatic Diseases
Bath, Somerset, United Kingdom